WallStSmart

Quipt Home Medical Corp (QIPT)vsSynergy CHC Corp. Common Stock (SNYR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Quipt Home Medical Corp generates 666% more annual revenue ($264.97M vs $34.59M). SNYR leads profitability with a 7.5% profit margin vs -4.0%. SNYR earns a higher WallStSmart Score of 45/100 (D).

QIPT

Hold

40

out of 100

Grade: D

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0

SNYR

Hold

45

out of 100

Grade: D

Growth: 4.3Profit: 6.0Value: 7.0Quality: 7.0
Piotroski: 4/9Altman Z: -0.45
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for QIPT.

SNYRUndervalued (+13.2%)

Margin of Safety

+13.2%

Fair Value

$1.90

Current Price

$1.17

$0.73 discount

UndervaluedFair: $1.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

QIPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
32.0%10/10

Revenue surging 32.0% year-over-year

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

SNYR2 strengths · Avg: 10.0/10
P/E RatioValuation
4.2x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-3.0410/10

Conservative balance sheet, low leverage

Areas to Watch

QIPT4 concerns · Avg: 2.5/10
Market CapQuality
$162.30M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.5%3/10

Operating margin of 1.5%

Return on EquityProfitability
-9.3%2/10

ROE of -9.3% — below average capital efficiency

EPS GrowthGrowth
-97.7%2/10

Earnings declined 97.7%

SNYR4 concerns · Avg: 2.5/10
Market CapQuality
$13.16M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
7.5%3/10

7.5% margin — thin

Return on EquityProfitability
-3.6%2/10

ROE of -3.6% — below average capital efficiency

EPS GrowthGrowth
-90.6%2/10

Earnings declined 90.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : QIPT

The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.

Bull Case : SNYR

The strongest argument for SNYR centers on P/E Ratio, Debt/Equity. Revenue growth of 12.4% demonstrates continued momentum.

Bear Case : QIPT

The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.

Bear Case : SNYR

The primary concerns for SNYR are Market Cap, Profit Margin, Return on Equity.

Key Dynamics to Monitor

QIPT profiles as a hypergrowth stock while SNYR is a value play — different risk/reward profiles.

SNYR carries more volatility with a beta of 1.27 — expect wider price swings.

QIPT is growing revenue faster at 32.0% — sustainability is the question.

QIPT generates stronger free cash flow (7M), providing more financial flexibility.

Bottom Line

SNYR scores higher overall (45/100 vs 40/100) and 12.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quipt Home Medical Corp

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.

Synergy CHC Corp. Common Stock

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Synergy CHC Corp. The company is headquartered in Westbrook, Maine.

Want to dig deeper into these stocks?